BPMC Blueprint Medicines Corp. Forward P/S Multiple

Has Blueprint Medicines (BPMC) successfully transformed laboratory research into a profitable business? The answer lies in the optimization of rare component supply chains, which ensures production stability. The forward P/S multiple confirms the efficiency of the platform for discovering drugs targeting genetic mutations, while the value of 14.90 determines the current status of the parameter amid the rapid sales growth of the mastocytosis drug.

BPMC (Blueprint Medicines Corporation) Price to Expected Revenue Ratio history from 07/04/2022 to 08/02/2025

Blueprint Medicines Corp - analytical breakdowns and key metrics (BPMC)

- current price and projected stock value:

Stock Price Blueprint Medicines Corp|BPMC - Analyst Target Range

- market capitalization data:

Market Capitalization Blueprint Medicines Corporation|BPMC - Total Enterprise Value

- issuer book value statistics:

Accounting Value per Share Blueprint Medicines|BPMC - Total Net Assets|Market Capitalization to Book Value Ratio blueprintmedicines.com|BPMC - Company Assets

- debt and liquidity data:

Total Debt to Capital Blueprint Medicines|BPMC - Long-Term Debt to Capital Ratio|Short-Term Debt to Equity Ratio Blueprint Medicines|BPMC - Aggregate Debt Obligations|Debt to Book Value Blueprint Medicines Corporation|BPMC - Amount of Long-Term Liabilities|Company Short-Term Debts Blueprint Medicines|Quick Ratio blueprintmedicines.com

- net income and valuation multiples indicators:

BPMC - Company Net Income|Expected Profit Blueprint Medicines|BPMC - Company Value to Net Income|Forward P/E Multiple Blueprint Medicines Corp.|BPMC - PEG Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Blueprint Medicines|BPMC - Profit before deduction of interest, taxes, depreciation and amortization|Net earnings per share for the last 12 months Blueprint Medicines|BPMC - Net earnings per one share for the last twelve months|Quarterly EPS earnings growth blueprintmedicines.com|BPMC - Earnings per share growth in current year|Net earnings per share growth forecast for next year Blueprint Medicines

- issuer revenue and sales details:

BPMC - Company Revenue|Company Future Sales Volume Blueprint Medicines Corp.|BPMC - P/S Multiple|Forward P/S Multiple Blueprint Medicines Corporation

Summary company analysis:Blueprint Medicines Corp (BPMC)

Product sample of Blueprint Medicines Corp.

The forward P/S ratio assesses the market value of a business relative to expected sales volume, making it possible to determine whether an asset is overvalued or undervalued in a hypothetical acquisition. By analyzing the projected price-to-sales ratio, an investor can see how the logistics resilience of rare components at Blueprint Medicines (BPMC) and protection against substance shortages support operating profitability, thereby influencing the investment attractiveness of the multiple.

Competing companies